See more : Great Microwave Technology Co., Ltd. (688270.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Better Therapeutics, Inc. (BTTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Better Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Tamagawa Holdings Co., Ltd. (6838.T) Income Statement Analysis – Financial Results
- Thiru Arooran Sugars Limited (THIRUSUGAR.NS) Income Statement Analysis – Financial Results
- Doseology Sciences Inc. (MOOD.CN) Income Statement Analysis – Financial Results
- Pacific Booker Minerals Inc. (PBMLF) Income Statement Analysis – Financial Results
- Daybreak Oil and Gas, Inc. (DBRM) Income Statement Analysis – Financial Results
Better Therapeutics, Inc. (BTTX)
About Better Therapeutics, Inc.
Better Therapeutics, Inc. engages in developing software-based prescription digital therapeutics (PDT) platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions in the United States. Its lead product candidate in development is BT-001, an investigational PDT platform that uses digitally delivered Nutritional Cognitive Behavioral Therapy to treat type 2 diabetes. The company's products under development also include BT-002, a PDT that help patients with hypertension improve their blood pressure; and BT-003, a PDT that help patients with hyperlipidemia enhance cholesterol levels. Better Therapeutics, Inc. was founded in 2015 and is headquartered in San Francisco, California.
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 8.00K | 18.00K |
| Cost of Revenue | 2.73M | 1.62M | 682.00K | 898.00K |
| Gross Profit | -2.73M | -1.62M | -674.00K | -880.00K |
| Gross Profit Ratio | 0.00% | 0.00% | -8,425.00% | -4,888.89% |
| Research & Development | 16.44M | 19.44M | 2.98M | 2.29M |
| General & Administrative | 14.84M | 8.79M | 2.46M | 2.20M |
| Selling & Marketing | 6.98M | 2.34M | 216.00K | 406.00K |
| SG&A | 21.82M | 11.12M | 2.67M | 2.60M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 38.26M | 30.56M | 5.65M | 4.89M |
| Cost & Expenses | 38.26M | 30.56M | 6.33M | 5.79M |
| Interest Income | 1.49K | 185.00 | 100.00 | 11.00 |
| Interest Expense | 1.49M | 185.00K | 100.00K | 11.00K |
| Depreciation & Amortization | 2.73M | 1.62M | 75.00K | 72.00K |
| EBITDA | -38.26M | -30.56M | -6.25M | -5.70M |
| EBITDA Ratio | 0.00% | 0.00% | -78,100.00% | -31,672.22% |
| Operating Income | -38.26M | -30.56M | -6.32M | -5.77M |
| Operating Income Ratio | 0.00% | 0.00% | -79,037.50% | -32,072.22% |
| Total Other Income/Expenses | -1.49M | -9.93M | 89.00K | -11.00K |
| Income Before Tax | -39.75M | -40.49M | -6.23M | -5.78M |
| Income Before Tax Ratio | 0.00% | 0.00% | -77,925.00% | -32,133.33% |
| Income Tax Expense | 7.00K | -153.00K | 153.00K | 11.00K |
| Net Income | -39.76M | -40.34M | -6.39M | -5.80M |
| Net Income Ratio | 0.00% | 0.00% | -79,837.50% | -32,194.44% |
| EPS | -1.69 | -1.71 | -0.85 | -0.25 |
| EPS Diluted | -1.69 | -1.71 | -0.85 | -0.25 |
| Weighted Avg Shares Out | 23.56M | 23.60M | 7.56M | 23.60M |
| Weighted Avg Shares Out (Dil) | 23.56M | 23.60M | 7.56M | 23.60M |
Why Is Better Therapeutics (BTTX) Stock Up 27% Today?
Source: Minerva Studio / Shutterstock.com Better Therapeutics (NASDAQ: BTTX ) stock is rocketing higher on Thursday as investors react to results from a Phase 2 clinical trial. This Phase 2 study saw Better Therapeutics using BT-001 to treat type 2...
Better Therapeutics Completes Pivotal Trial of BT-001 for Type 2 Diabetes and Announces Positive Secondary Endpoint Results Following the Earlier Announcement of Positive Primary Endpoint Results
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (“Better Therapeutics”, NASDAQ: BTTX), a prescription digital therapeutics company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced the completion of the pivotal clinical trial for BT-001, an...
Better Therapeutics to Host Conference Call to Review Results from Pivotal Clinical Trial of BT-001 for Type 2 Diabetes
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today announced it will host a conference call and webcast on Thursday, July...
3 Penny Stocks That Have Huge Catalysts Ahead
While you don't want to play with money you can't afford to lose, these penny stocks might bring home the goods for the bold. The post 3 Penny Stocks That Have Huge Catalysts Ahead appeared first on InvestorPlace.
Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop
This week's list of potential short squeeze stocks from Fintel is certainly drawing attention, with some big names featured on the list. The post Short Squeeze Stocks: RDBX, BTTX and 3 Others Experts Think Are Ready to Pop appeared first...
5 Short Squeeze Candidates To Watch This Week: Redbox Tops List With Huge Numbers, GameStop Rejoins The Leaderboard Ahead Of Earnings
Potential short squeeze plays gained steam in 2021, with new retail traders looking for the next huge move. A short squeeze can occur when a heavily shorted stock rises in value instead of falling.
5 Top Penny Stocks For Your Watch List In June 2022
Top penny stocks to watch in June 2022 The post 5 Top Penny Stocks For Your Watch List In June 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Top 3 Penny Stocks Outperforming the Stock Market in May 2022
Why these penny stocks are climbing right now The post Top 3 Penny Stocks Outperforming the Stock Market in May 2022 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Better Therapeutics' (BTTX) CEO Kevin Appelbaum on Q1 2022 Results - Earnings Call Transcript
Better Therapeutics, Inc. (NASDAQ:BTTX ) Q1 2022 Earnings Conference Call May 13, 2022 8:30 AM ET Company Participants Kevin Appelbaum – Co-Founder and Chief Executive Officer Mark Berman – Chief Medical Officer Mark Heinen – Chief Financial Officer Conference Call...
Better Therapeutics Reports First Quarter 2022 Financial Results and Provides Update on Key Corporate Milestones
SAN FRANCISCO--(BUSINESS WIRE)--Better Therapeutics, Inc. (NASDAQ: BTTX), a prescription digital therapeutics (PDT) company developing nutritional cognitive behavioral therapy (nCBT) to address the root causes of cardiometabolic diseases, today reported financial results for the first quarter of 2022 and provided an...
Source: https://incomestatements.info
Category: Stock Reports